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Vagal nerve stimulation using an NCP (Cyberonics) device has been suggested as a potential treatment for patients with epilepsy
that has previously proven refractory. Ten patients in Northern Ireland have had this device implanted and been fully audited pre-
and post-operatively. Twelve months post-implantation, five patients have demonstrated a greater than 50% reduction in seizure
frequency. A statistical reduction in seizure severity of the ictal phase of the major seizures has also been shown. Improvement
in the patients’ overall quality of life has, however, not been demonstrated in parallel to seizure reduction.
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INTRODUCTION
Preliminary results from clinical trials1, 2 of vagal
stimulation from implanted electrodes with a neuro-
cybernetic prosthesis (NCP; Cyberonics) have given
initial indications that this device may be effective in
reducing complex partial seizures in patients who had
previously proven to be refractory to drug therapy. A
number of multi-centre randomized active controlled
trials have also demonstrated the efficacy of this device
in reducing seizure frequency in patients with partial
onset seizures3, 4.
In Northern Ireland, to date, 15 patients have had
the NCP (Cyberonics) device implanted. The first 10
patients to undergo implantation have now been fol-
lowed up for periods in excess of 12 months. These
patients have been carefully audited pre- and post-
operatively.
SUBJECTS
All patients selected for the vagal nerve stimulation
had previously proven to have refractory epilepsy of
a partial onset. All had been exposed to every exist-
ing conventional and novel antiepileptic medication
available on prescription. All 10 were continuing to
take medication often in polytherapy. All 10 patients
had also been previously assessed for their suitability
for more definitive surgical intervention, e.g. temporal
lobectomy and had been found unsuitable.
The first 10 patients implanted were nine males
and one female. Patients were aged 16 to 54 years
(mean: 32 years). Six patients had an associated (mild)
learning disability. All 10 patients had complex par-
tial seizures and nine also suffered from secondarily
generalized tonic–clonic seizures. Seizure frequency,
pre-operatively ranged from 5–52 seizures per month
(mean: 15 seizures per month; median: 12 seizures per
month). The duration of epilepsy ranged from 16 to
47 years (mean: 27 years). Patients were taking, and
continued to take, for at least the first 12 months of
the study, their regular medication. Cases were taking
a range of one to three antiepileptic drugs per patient
(mean: 2.5 antiepileptic drugs per patient).
In all cases a detailed baseline assessment had been
carried out in the months prior to surgery. Patients
were required to complete seizure diaries record-
ing seizure frequency and type throughout the study
period. Seizure severity scores using the Liverpool
Seizure Severity Scale5 were compiled at 3-monthly
intervals. An assessment of quality of life utilizing
1059–1311/00/060442 + 04 $35.00/0 c© 2000 BEA Trading Ltd
Vagal nerve stimulation in patients with refractory epilepsy 443
–100
–80
–60
–40
% Increase
% Decrease
–20
0
20
40
Fig. 1: Change in seizure frequency at 12 months compared with baseline. Each bar represents a single patient’s percentage
change in seizure frequency in average no. of seizures per month, measured over the preceding 3 months and compared with the
average no. of seizures per month for 3 months pre-implantation.
the Rank Health Scale was completed pre-operatively
and at 12 months post-implantation. Eight of the 10
patients completed these two questionnaires. Learn-
ing disability was the limiting factor in the other two
cases. Patients were seen at regular intervals at outpa-
tients following implantation. The milliampage output
stimulus of the device was increased at each outpatient
visit to the maximum tolerated. For the first 12 months
the parameters chosen were those that had been used
in the previously reported studies. The device was pro-
grammed to fire (ON) for 30 seconds and remain inac-
tive (OFF) for 5 minutes.
For those patients who did not appear to respond af-
ter 12 months to the standard firing parameters, the
device was changed to a rapid-cycle firing parameter.
This firing pattern set the device to fire (ON) for 7 sec-
onds and (OFF) for 30 seconds.
RESULTS
Seizure frequency and severity
Follow-up post-implantation has been for a mean of
18 months (range 12–36 months). Nine patients re-
main on the 30 seconds ON, 5 minutes OFF parameter.
One patient at the time of completion of this study had
been switched to the rapid-cycle sequence. The mean
end output current was 2.5 milliamps (range: 1–3 mil-
liamps). The percentage change in seizure frequency
per patient at 12 months post-implantation compared
with baseline is shown in Fig. 1. Two patients had
a small rise in seizure frequency, two remained un-
changed, five of the 10 patients at this treatment in-
terval demonstrated a greater than 50% reduction in
seizure frequency over baseline.
Two patients demonstrated a greater than 80% re-
duction in seizure frequency. No patients became
seizure free. The percentage change in seizure fre-
quency of the group as a whole over time is shown
in Fig. 2. The overall percentage reduction in seizure
frequency over time for the group as a whole was ap-
proximately 30%. This reduction appeared to be main-
tained over time, although the numbers at follow-up
intervals fell due to different implantation times. At-
tempts to reduce drug load over time generally did
not prove successful. Seizure severity scores were
measured using the Liverpool Seizure Severity Scale.
Eight patients completed this questionnaire. At 12
months there was a significant (P = 0.03, Wilcoxon
signed ranks test) reduction in the ictal phase of the
major seizures (Fig. 3). This reduction correlated with
subjective reports from patients and relatives of a re-
duction in seizure severity. There was, however, no re-
duction in the other seizure severity scores.
Adverse events
Adverse events were recorded at each outpatient
follow-up visit. One patient reported post-operative
hoarseness; this disappeared spontaneously after a few
months. Transient hoarseness related to firing (ON)
was common and was recorded in 5 of the 10 patients.
Coughing, again transient and related to firing (ON),
was also reported in two patients. Both of these symp-
toms were transient and tended to wear off in the few
days succeeding an increase in the output current. No
cognitive or other effects were reported. One patient
died during follow-up; this patient had had the device
for in excess of 12 months. There had been no recent
manipulation in his output current. It was reported by
his parents that he had had a seizure and had subse-
quently been found dead in bed. A full autopsy was
performed. The NCP device was found to be working
normally. His death was attributed to a sudden unex-
pected death in epilepsy (SUDEP).
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Fig. 2: Percentage change in seizure frequency of the group over time compared with baseline.
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Fig. 3: Seizure severity scores (Liverpool Seizure Severity Scale) at baseline and 12 months.
Quality of life measures
Patients were asked directly how they related their
health at 12 months to how they had been prior to the
implantation of the vagal nerve stimulator. The overall
scores suggested that they regarded their health sub-
jectively as about the same as before the device had
been implanted.
On a linear scale patients (n = 8) were asked to
rate their quality of life: from the best possible qual-
ity of life to worst possibility of life. The results at 12
months were identical to those obtained at baseline.
Patients were asked about limitations to home, social
and work activities. There was no reduction in the lim-
itations reported at 12 months compared to baseline
(n = 8).
DISCUSSION
Vagal nerve stimulation is becoming increasingly
available throughout North America and the UK as
a potential treatment for epilepsy that has previously
prove refractory to both medical and surgical inter-
ventions. A theoretical basis for its efficacy exists and
earlier multi-centre trials have demonstrated this effi-
cacy. Its utilization as a standard and accepted treat-
ment within the NHS, however, remains controver-
sial. Each of the patients presented in this study was
provided with individual funding from their relevant
health board.
The results from our audit of these patients is
very much in line with similar studies carried out
elsewhere. An overall reduction in seizure frequency
across the group of 30% is of the order demonstrated
in other similar studies3, 4. Such a reduction in seizure
frequency may appear small, yet this level of reduction
in seizure frequency is similar to that demonstrated by
all of the newer antiepileptics drugs in their clinical tri-
als. No patients in this group became seizure free, al-
though two had a greater than 80% reduction in seizure
frequency. At this time, however, there is no method
of differentiating responders from non-responders pre-
operatively.
The spectrum of adverse effects seen with this
mode of therapy are entirely different to those seen
with antiepileptic drugs for which cognitive and be-
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havioural effects are most common. The effects re-
ported in this study and others largely reflect upon the
direct stimulus applied to the left vagal nerve and were
generally transient. The device was generally well tol-
erated. This may suggest advantage in the treatment
of patients with learning disability in particular, as in
these patients, who often demonstrate quite refractory
epilepsy, cognitive and behavioural effects of medica-
tion often prove limiting factors.
One patient in this study group died. His death
was attributed, after post-mortem, to SUDEP. Sud-
den unexpected death is a recognized complication of
epilepsy6. Although relatively uncommon, those rec-
ognized at greatest risk are young people with severe
and uncontrolled epilepsy. Previous studies7 have ad-
dressed the possible effects of vagal nerve stimulation
on gastric acid secretion and on cardiac rhythm with
no significant effects being demonstrated.
Despite recorded reduction in seizure frequency and
subjective reports of reduction in seizure severity, no
improvement in quality of life was demonstrated using
the measures chosen. This may reflect upon the rela-
tive insensitivity of these measures or upon the fact
that quality of life and seizure frequency do not bear a
linear relationship.
Cost implications need also to be considered. Each
implantable device costs around £5000, plus there is
the cost of surgery. The battery will last for about 5
years, depending on usage, and then need to be re-
placed, again at surgery. The initial cost has had the ef-
fect of limiting the use of this treatment technique, yet
given the annual cost of the newer antiepileptic drugs
(approx. £800–£1500 per year) and the not dissimilar
results on seizure frequency, vagal nerve stimulation
does not compare unfavourably. Further evidence of
the effects on overall quality of life, particularly in the
longer term, for patients offered this treatment is, how-
ever, required.
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